iBio, Inc. (iBio) is a biotechnology company focused on commercializing its technologies, the iBioLaunch platform for vaccines and therapeutic proteins, as well as the iBioModulator platform for vaccine enhancement. Vaccine candidates on its platform are applicable to newly emerging strains of hemagglutinin type 1 and neuraminidase type 1 (H1N1), swine-like influenza, hemagglutinin type 5 and neuraminidase type 1 (H5N1) avian influenza, yellow fever, and anthrax. The Company licenses or otherwise grants use rights to government and non-governmental organization (NGO) entities for not-for-profit applications of the intellectual property for the development or application for which they granted or were granted funding, and to Fraunhofer USA, Inc. (FhCMB) for research purposes and applications in other fields.